Deals Of The Week: Genentech/Constellation, Bayer/Ventana, Genzyme/Veracyte
By
Paul Bonanos, Joseph Haas, Sue Sutter, Jessica Merrill, Mark Ratner / Email the Authors / “The Pink Sheet” Jan. 23, 2012, Vol. 74, No. 4
Business & Finance / Word Count: 1115 / Article # 00120123011
Executive Summary
Epigenetics took the spotlight this week, with Genentech being the latest pharma to move into the field in partnership with Constellation Pharmaceuticals. In other deals, Bayer signed Ventana to develop a companion diagnostic, and Pfizer walked away from Medivation and Alzheimer’s drug Dimebon.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.